4 weeks Down -42.2% in 4 Weeks, Here’s Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround Zacks

Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Earnings · Wall Street